Amzeeq – Health

Amzeeq Now Available for Moderate to Severe Acne – Monthly Prescribing Reference

Amzeeq (minocycline; Foamix) topical foam 4% will soon be available (January 13, 2020) by prescription for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients aged 9 years and older. Amzeeq utilizes Foamix’s proprietary Molecule Stabilizing Technology (MST) platform to deliver minocycline, a tetracycline-class drug, in a foam formulation; it… Read More »

FDA Approves Amzeeq (minocycline) Topical Foam for the Treatment of Moderate to Severe Acne

FDA Approves Amzeeq (minocycline) Topical Foam for the Treatment of Moderate to Severe Acne Print this page REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 18, 2019 (GLOBE NEWSWIRE) — Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved its novel… Read More »